Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety,
tolerability and pharmacokinetic/pharmacodynamics characteristics of Human CD19-CD22 Targeted
T Cells Injection, and to preliminarily observe the efficacy of the trial drug in patients
with central nervous system involvement of refractory/relapsed B cell malignancies.